{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:06:12Z","timestamp":1760123172056,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.03.055","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T21:13:28Z","timestamp":1650575608000},"page":"3253-3262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Justin R.","family":"Ortiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaitlyn","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Buddy Creech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbur H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar T.","family":"Overton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Dickey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather L.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Wegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.03.055_b0005","unstructured":"Centers for Disease Control and Prevention. Asian Lineage Avian Influenza A (H7N9) Virus. Available from: https:\/\/www.cdc.gov\/flu\/avianflu\/h7n9-virus.htm. Accessed 17 May 2021."},{"key":"10.1016\/j.vaccine.2022.03.055_b0010","unstructured":"World Health Organization Western Pacific Region. Avian Influenza Weekly Update Number 791. Available from: https:\/\/www.who.int\/docs\/default-source\/wpro---documents\/emergency\/surveillance\/avian-influenza\/ai-20210507.pdf. Accessed 17 May 2021."},{"key":"10.1016\/j.vaccine.2022.03.055_b0015","unstructured":"World Health Organization. Influenza at the human-animal interface: Summary and assessment, from 28 February to 8 May 2020. Available from: https:\/\/www.who.int\/influenza\/human_animal_interface\/Influenza_Summary_IRA_HA_interface_08_05_2020.pdf. Accessed 17 May 2021."},{"key":"10.1016\/j.vaccine.2022.03.055_b0020","unstructured":"World Health Organization. Analysis of recent scientific information on avian influenza A(H7N9) virus. Available from: https:\/\/www.who.int\/influenza\/human_animal_interface\/avian_influenza\/riskassessment_AH7N9_201702\/en\/. Accessed 17 May 2021."},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.055_b0025","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/cid\/ciy541","article-title":"Assessment of human-to-human transmissibility of avian influenza A(H7N9) virus across 5 waves by analyzing clusters of case patients in Mainland China, 2013\u20132017","volume":"68","author":"Wang","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.055_b0030","unstructured":"World Health Organization. Influenza at the human-animal interface: Summary and assessment, 13 February to 9 April 2019. Available from: https:\/\/www.who.int\/influenza\/human_animal_interface\/Influenza_Summary_IRA_HA_interface_09_04_2019.pdf?ua=1. Accessed 17 May 2021."},{"issue":"35","key":"10.1016\/j.vaccine.2022.03.055_b0035","doi-asserted-by":"crossref","first-page":"928","DOI":"10.15585\/mmwr.mm6635a2","article-title":"Update: increase in human infections with novel asian lineage avian influenza A(H7N9) viruses during the fifth epidemic - China, October 1, 2016-August 7, 2017","volume":"66","author":"Kile","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.03.055_b0040","unstructured":"Centers for Disease Control and Prevention. Summary of Influenza Risk Assessment Tool (IRAT) Results. Available from: https:\/\/www.cdc.gov\/flu\/pandemic-resources\/monitoring\/irat-virus-summaries.htm. Accessed 17 May 2021."},{"issue":"7","key":"10.1016\/j.vaccine.2022.03.055_b0045","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/14760584.2017.1334554","article-title":"Repeated annual influenza vaccination and vaccine effectiveness: review of evidence","volume":"16","author":"Belongia","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2022.03.055_b0050","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0264-410X(97)00003-0","article-title":"Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period","volume":"15","author":"Keitel","year":"1997","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.03.055_b0055","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/cid\/cit060","article-title":"Influenza vaccine effectiveness in the community and the household","volume":"56","author":"Ohmit","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"28","key":"10.1016\/j.vaccine.2022.03.055_b0060","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1016\/j.vaccine.2012.04.044","article-title":"Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009","volume":"30","author":"Chen","year":"2012","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.03.055_b0065","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1348-0421.2011.00381.x","article-title":"Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial","volume":"55","author":"Uno","year":"2011","journal-title":"Microbiol Immunol"},{"issue":"9708","key":"10.1016\/j.vaccine.2022.03.055_b0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(09)62039-0","article-title":"Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009\u201310 influenza season: a multicentre, randomised controlled trial","volume":"375","author":"Vajo","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2022.03.055_b0075","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/cid\/ciu680","article-title":"Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons","volume":"59","author":"McLean","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.03.055_b0080","unstructured":"World Health Organization. Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. Available from: https:\/\/www.who.int\/influenza\/vaccines\/virus\/recommendations\/201703_recommendation.pdf. Accessed 7\/7\/21."},{"issue":"47","key":"10.1016\/j.vaccine.2022.03.055_b0085","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1016\/j.vaccine.2009.03.015","article-title":"Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A\/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults","volume":"27","author":"Keitel","year":"2009","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.vaccine.2022.03.055_b0090","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.055_b0095","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/CVI.00368-08","article-title":"Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure","volume":"16","author":"Noah","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.03.055_b0100","unstructured":"US Food and Drug Agency. Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. Available from: https:\/\/www.fda.gov\/media\/73691\/download. Accessed 16 March 2021."},{"issue":"3","key":"10.1016\/j.vaccine.2022.03.055_b0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.vaccine.2022.03.055_b0110","doi-asserted-by":"crossref","first-page":"e49704","DOI":"10.1371\/journal.pone.0049704","article-title":"A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine","volume":"7","author":"Couch","year":"2012","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2022.03.055_b0115","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/INF.0b013e3181daf921","article-title":"Immunogenicity and Safety of H5N1 A\/Vietnam\/1194\/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study","volume":"29","author":"D\u00edez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"9587","key":"10.1016\/j.vaccine.2022.03.055_b0120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(07)61297-5","article-title":"Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial","volume":"370","author":"Leroux-Roels","year":"2007","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.vaccine.2022.03.055_b0125","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.03.055_b0130","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/erv.09.5","article-title":"Emulsion-based adjuvants for influenza vaccines","volume":"8","author":"Vogel","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.03.055_b0135","unstructured":"World Health Organization. Human infection with avian influenza A(H7N9) virus \u2013 China: Update. Available from: https:\/\/www.who.int\/csr\/don\/05-september-2018-ah7n9-china\/en\/. Accessed 3\/16\/2021."},{"key":"10.1016\/j.vaccine.2022.03.055_b0140","unstructured":"World Health Organization. Human infection with avian influenza A (H5N8) \u2013 the Russian Federation. Available from: https:\/\/www.who.int\/csr\/don\/26-feb-2021-influenza-a-russian-federation\/en\/. Accessed 8 March 2021."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22003668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22003668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:11:12Z","timestamp":1759403472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22003668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":28,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22003668"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.055","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}